Benefits of catch-up in vaccination against human papillomavirus in medium- and low-income countries

International Journal of Cancer

Volumn 133, Issue 8, 2013, Pages 1876-1881

  Baussano, Iacopo ^a   Lazzarato, Fulvio ^b   Ronco, Guglielmo ^c   Dillner, Joakim ^d   Franceschi, Silvia ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b UNIVERSITY OF TURIN   (Italy)

^c Centre for Cancer Prevention (CPO Piemonte)   (Italy)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

adolescent girls; catch up; HPV vaccination

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; AGE; ARTICLE; CATCH UP VACCINATION; CHILD; FEMALE; GUINEA; HERD IMMUNITY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; LOWEST INCOME GROUP; POLAND; PREVALENCE; PRIORITY JOURNAL; PROBABILITY; SCHOOL CHILD; SEXUAL BEHAVIOR; UTERINE CERVIX CANCER; VACCINATION; VIRUS TRANSMISSION;

ADOLESCENT GIRLS; CATCH-UP; HPV VACCINATION;

ADOLESCENT; AGE FACTORS; CHILD; COST-BENEFIT ANALYSIS; DEVELOPED COUNTRIES; DEVELOPING COUNTRIES; FEMALE; GUINEA; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; MASS VACCINATION; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; POLAND; PREVALENCE; UTERINE CERVICAL NEOPLASMS; VACCINATION; YOUNG ADULT;

EID: 84881542613     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28197     Document Type: Article

References (37)

1. World Health Organization. Human papillomavirus vaccines. WHO position paper. Wkly Epidemiol Rec 2009; 84: 118-31.
2. Cancer Cervical Action. Progress in cervical cancer prevention: the CCA Report Card. January 2012. Cancer Cervical Action 2012. Available at: http://www.cervicalcanceraction.org/pubs/CCA-reportcard-low-res.pdf (Accessed August 27, 2012).
3. Bonanni P, Levi M, Latham NB, et al. An overview on the implementation of HPV vaccination in Europe. Hum Vaccin 2011; 7 (Suppl): 128-35.
4. GAVI. GUIDELINES FOR APPLICATIONS 2012 Human Papillomavirus (HPV) Vaccination Demonstration Programme. GAVI 2012. Available at: http://www.gavialliance.org/library/documents/gavi-documents/ guidelines-And-forms/application-guidelines-for-hpv-vaccination-demonstration- programmes/ (Accessed August 27, 2012).
5. Baussano I, Garnett G, Segnan N, et al. Modelling patterns of clearance of HPV-16 infection and vaccination efficacy. Vaccine 2011; 29: 1270-7.
6. Bardin A, Vaccarella S, Clifford GM, et al. Human papillomavirus infection in women with and without cervical cancer in Warsaw, Poland. Eur J Cancer 2008; 44: 557-64.
7. Keita N, Clifford GM, Koulibaly M, et al. HPV infection in women with and without cervical cancer in Conakry, Guinea. Br J Cancer 2009; 101: 202-8.
8. Franceschi S, Herrero R, Clifford GM, et al. Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. Int J Cancer 2006; 119: 2677-84.
9. Ronco G, Giorgi-Rossi P, Carozzi F, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol 2010; 11: 249-57.
10. Hoare A, Regan DG, Wilson DP,. Sampling and sensitivity analyses tools (SaSAT) for computational modelling. Theor Biol Med Model 2008; 5: 4.
11. Garnett GP, Anderson RM,. Factors controlling the spread of HIV in heterosexual communities in developing countries: patterns of mixing between different age and sexual activity classes. Philos Trans R Soc Lond B Biol Sci 1993; 342: 137-59.
12. Choi YH, Jit M, Gay N, et al. Transmission dynamic modelling of the impact of human papillomavirus vaccination in the United Kingdom. Vaccine 2010; 28: 4091-102.
13. Jit M, Chapman R, Hughes O, et al. Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model. BMJ 2011; 343: d5775.
14. Rositch AF, Burke AE, Viscidi RP, et al. Contributions of recent and past sexual partnerships on incident human papillomavirus detection: acquisition and reactivation in older women. Cancer Res 2012; 72: 6183-90.
15. Safaeian M, Porras C, Schiffman M, et al. Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections. J Natl Cancer Inst 2010; 102: 1653-62.
16. Szarewski A, Poppe WA, Skinner SR, et al. Efficacy of the human papillomavirus (HPV)-16/18 AS04-Adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18. Int J Cancer 2012; 131: 106-16.
17. Trottier H, Ferreira S, Thomann P, et al. Human papillomavirus infection and reinfection in adult women: the role of sexual activity and natural immunity. Cancer Res 2010; 70: 8569-77.
18. Paavonen J, Naud P, Salmeron J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-Adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009; 374: 301-14.
19. Wheeler CM, Kjaer SK, Sigurdsson K, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis 2009; 199: 936-44.
20. Binagwaho A, Wagner CM, Gatera M, et al. Achieving high coverage in Rwanda's national human papillomavirus vaccination programme. Bull World Health Organ 2012; 90: 623-8.
21. Watson-Jones D, Baisley K, Ponsiano R, et al. Human papillomavirus vaccination in Tanzanian schoolgirls: cluster-randomized trial comparing 2 vaccine-delivery strategies. J Infect Dis 2012; 206: 678-86.
22. Brotherton J, Gertig D, Chappell G, et al. Catching up with the catch-up: HPV vaccination coverage data for Australian women aged 18-26 years from the National HPV Vaccination Program Register. Commun Dis Intell 2011; 35: 197-201.
23. Vaccarella S, Franceschi S, Snijders PJ, et al. Concurrent infection with multiple human papillomavirus types: pooled analysis of the IARC HPV prevalence surveys. Cancer Epidemiol Biomarkers Prev 2010; 19: 503-10.
24. Carozzi F, Ronco G, Gillio-Tos A, et al. Concurrent infections with multiple human papillomavirus (HPV) types in the New Technologies for Cervical Cancer (NTCC) screening study. Eur J Cancer 2012; 48: 1633-7.
25. Vaccarella S, Franceschi S, Herrero R, et al. Clustering of multiple human papillomavirus infections in women from a population-based study in Guanacaste, Costa Rica. J Infect Dis 2011; 39: 1179-89.
26. Garnett GP,. Role of herd immunity in determining the effect of vaccines against sexually transmitted disease. J Infect Dis 2005; 191 (Suppl 1): S97-106.
27. Kreimer AR, Rodriguez AC, Hildesheim A, et al. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst 2011; 103: 1444-51.
28. Garnett GP,. The geographical and temporal evolution of sexually transmitted disease epidemics. Sex Transm Infect 2002; 78 (Suppl 1): i14-i19.
29. Soderlund-Strand A, Dillner J,. High throughput monitoring of human papillomavirus type distribution. Cancer Epidemiol Biomarkers Prev 2013; 22: 242-50.
30. Li N, Franceschi S, Howell-Jones R, Snijders PJ, et al. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. Int J Cancer 2011; 128: 927-35.
31. Lehtinen M, Paavonen J, Wheeler CM, et al. Overall efficacy of HPV-16/18 AS04-Adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012; 13: 89-99.
32. Liljeros F, Edling CR, Nunes Amaral LA,. Sexual networks: implications for the transmission of sexually transmitted infections. Microbes Infect 2003; 5: 189-96.
33. Widdice LE, Breland DJ, Jonte J, et al. Human papillomavirus concordance in heterosexual couples. J Adolesc Health 2010; 47: 151-9.
34. Jit M, Choi YH, Edmunds WJ,. Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ 2008; 337: a769.
35. Baggaley RF, Garnett GP, Ferguson NM,. Modelling the impact of antiretroviral use in resource-poor settings. PLoS Med 2006; 3: e124.
36. Goldie SJ, O'Shea M, Campos NG, et al. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries. Vaccine 2008; 26: 4080-93.
37. Eisenstein M,. Public health: prevention comes of age. Nature 2012; 488: S11-S13.